



Impact of vitamin D₃ supplementation on the *in vitro* growth of mouse preantral follicles

Yoo Jin Shim^{1,2,*}, Yeon Hee Hong^{2,3,*}, Jaewang Lee⁴, Byung Chul Jee^{2,5}

¹Department of Obstetrics and Gynecology, Dongguk University Ilsan Medical Center, Ilsan; ²Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul; ³Department of Health Promotion Center, Seoul National University Bundang Hospital, Seongnam; ⁴Department of Biomedical Laboratory Science, Eulji University College of Health Science, Seongnam; ⁵Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea

Objective: We investigated the impact of vitamin D₃ (VD₃) supplementation during mouse preantral follicle culture *in vitro* and the mRNA expression of 25-hydroxylase (*CYP2R1*), 1-alpha-hydroxylase (*CYP27B1*), and vitamin D receptor (*VDR*) in mouse ovarian follicles at different stages.

Methods: Preantral follicles were retrieved from 39 BDF1 mice (7–8 weeks old) and then cultured *in vitro* for 12 days under VD₃ supplementation (0, 25, and 50 pg/mL). Follicular development and the final oocyte acquisition were assessed. Preantral follicles were retrieved from 15 other BDF1 mice (7–8 weeks old) and cultured without VD₃ supplementation. Three stages of mouse ovarian follicles were obtained (preantral, antral, and ruptured follicles). Total RNA was extracted from the pooled cells (from 20 follicles at each stage), and then reverse transcriptase-polymerase chain reaction was performed to identify mRNA for *CYP2R1*, *CYP27B1*, and *VDR*.

Results: The survival of preantral follicles, rates of antrum formation and ruptured follicles (per initiated follicle) and the number of total or mature oocytes were all comparable among the three groups. Both *CYP2R1* and *CYP27B1* were expressed in antral and ruptured follicles, but not in preantral follicles. *VDR* was expressed in all three follicular stages.

Conclusion: VD₃ supplementation *in vitro* (25 or 50 pg/mL) did not enhance mouse follicular development or final oocyte acquisition. Follicular stage-specific expression of *CYP2R1*, *CYP27B1*, and *VDR* was observed.

Keywords: 1Alpha-hydroxylase; 25-Hydroxylase; Antral follicle; Calcitriol receptors; Cholecalciferol; Preantral follicle

Introduction

Vitamin D (VD) is a steroid hormone involved in calcium and phosphorus homeostasis and bone mineralization [1,2]. VD can be synthesized in the skin through sun exposure or obtained via food intake [1]. The serum level of VD can be affected by age, race, season, and body

mass index [2]. Two main enzymes are involved in the synthesis of VD [3]. Hepatic 25-hydroxylase converts VD to 25-hydroxyvitamin D (25OHD, 25-hydroxycholecalciferol; the major circulating form of VD), and renal 1-alpha-hydroxylase converts 25OHD to the active form 1,25-dihydroxyvitamin D₃ (1,25(OH)₂D₃, 1,25-hydroxycholecalciferol, calcitriol, VD₃) [4]. *CYP2R1* is the most important 25-hydroxylase, and *CYP27B1* is the key 1-alpha-hydroxylase. The active form VD₃ is the ligand for the vitamin D receptor (*VDR*), which is present in many female reproductive organs, such as the ovary, endometrium, fallopian tube, and placenta [3]. *VDR* is present particularly in granulosa cells of the ovarian follicles; therefore, it is believed that VD plays an essential role in ovarian follicular development [3,5,6].

In a human granulosa cell culture model, VD₃ supplementation *in vitro* enhanced 3-beta-hydroxysteroid dehydrogenase activity and progesterone production, but did not affect follicle-stimulating hormone (FSH)-induced aromatase activity and estradiol production [5].

Received: June 6, 2021 · Revised: July 14, 2021 · Accepted: July 16, 2021

Corresponding author: **Byung Chul Jee**

Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, 82 Gumi-ro 173-beon-gil, Bundang-gu, Seongnam 13620, Korea
 Tel: +82-31-787-7254 Fax: +82-31-787-4054 E-mail: blasto@snuh.org

*These authors contributed equally to this article.

*This work was supported by grant no. 02-2019-012 from the Seoul National University Bundang Hospital Research fund.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

In women with polycystic ovary syndrome, VD supplementation was beneficial for follicular development, with a higher number of dominant follicles and a more regular menstrual cycle [7].

In human *in vitro* fertilization (IVF) cycles, several studies have reported an association between higher serum or follicular fluid (FF) 25OHD concentrations and the clinical pregnancy rate; however, other studies have reported contradictory findings [3,6]. Furthermore, it was reported that FF 25OHD levels were inversely related to embryo quality [8,9]. Therefore, there are insufficient data to reach a definitive conclusion regarding the effect of VD supplementation for VD-depleted women undergoing IVF [6]. A few experiments have reported that VD3 supplementation had a direct effect on ovarian follicular development. In goats, VD3 supplementation *in vitro* during granulosa cell culture decreased the level of reactive oxygen species [10]. In rhesus macaques, VD3 supplementation *in vitro* increased preantral follicle survival up to the antral follicle stage [11,12].

However, no animal model studies have yet investigated the impact of VD3 supplementation *in vitro* on the entire folliculogenesis process, up to oocyte acquisition. We investigated whether VD3 supplementation *in vitro* affected follicular development and final oocyte acquisition in a mouse model of preantral follicle culture. We also investigated whether 25-hydroxylase, 1-alpha-hydroxylase, and VDR were expressed in the three stages of mouse ovarian follicles. If there VD3 supplementation is beneficial for follicular development, a rationale will be provided to recommend sufficient VD intake to improve IVF results.

Methods

1. Impact of VD3 supplementation *in vitro* on mouse preantral follicle development

Female 7- to 8-week old BDF1 mice (Orient Co., Seoul, Korea) were nurtured under 12-hour day and a 12-hour night conditions at 23°C and fed *ad libitum*. The Institutional Animal Care and Use Committee (IACUC) of Seoul National University Bundang Hospital approved the experiment (No. BA1903-267/014-01). After 1 week of adaptation, 39 mice were killed by cervical dislocation and bilateral ovaries were obtained. They were collected in 1 mL of L-15 medium (WelGENE, Daegu, Korea) supplemented with 0.4% bovine serum albumin (Sigma-Aldrich, St. Louis, MO, USA). From the ovaries, intact preantral follicles were isolated via mechanical tearing by a 1-mL tuberculin syringe [13] and randomly divided into three groups.

Preantral follicles were cultured in a growth medium containing alpha-minimum essential medium (WelGENE), 5% fetal bovine serum (Gibco, Paisley, UK), 10 mIU/mL recombinant FSH (Merck-Serono, Geneva, Switzerland), 1% insulin-transferrin-selenium mixture (Sigma-Aldrich), and 1% penicillin-streptomycin mixture (Sigma-Al-

drich). All follicles were cultured in 96-well plates (BD BioCoat; BD Falcon, Franklin Lakes, NJ, USA) at 37°C in 5% CO₂ for 10 days. Medium changes were conducted every other day, and follicle survival and antrum formation were assessed. If granulosa cells appeared to be dark and fragmented, they were considered to be dead.

After 10 days of culture in the growth medium, the follicles were transferred to maturation medium and cultured for another 16 hours at 37°C in 5% CO₂ to obtain ruptured follicles. The maturation medium was composed of 1.5 IU/mL human chorionic gonadotropin (Merck-Serono), and 5 ng/mL recombinant mouse epidermal growth factor (Sigma-Aldrich) was added to the growth medium. During the 12 days of culture, supplementation with 0, 25, and 50 pg/mL of active-form VD3 (1,25(OH)₂D₃, Sigma-Aldrich) was performed.

Oocytes were harvested from the finally ruptured (ovulated) follicles. Surrounding cumulus cells were removed by treatment with 0.3% hyaluronidase (Sigma-Aldrich) and gentle pipetting. Oocytes were classified into five categories; germinal vesicle (GV), GV breakdown, metaphase II (MII), degenerated, or dead. If a polar body was present in the perivitelline space, the oocytes were considered to be MII oocytes. Fragmented or dark oocytes were classified as degenerated. If the oocytes were not enclosed by granulosa cells, they were classified as dead. The analysis was performed by one skilled embryologist to minimize inter-observer variability.

2. Isolation of mRNA, cDNA synthesis, and reverse transcriptase-polymerase chain reaction

From 15 mice, preantral follicles were isolated and cultured in growth medium for 10 days and then transferred to maturation medium for 16 hours, as described above (without VD3 supplementation). Twenty follicles in each stage of folliculogenesis (preantral, antral, and ruptured follicles) were pooled, and the total RNA was extracted using the Dynabeads protocol (Dynabeads mRNA DIRECT Kit; Ambion, Oslo, Norway). The mRNA of *CYP2R1* (encoding 25-hydroxylase), *CYP27B1* (encoding 1-alpha-hydroxylase), and *VDR* was transcribed into cDNA using a PrimeScript first-strand cDNA Synthesis Kit (Takara, Kusatsu, Japan) according to the manufacturer's instructions. Each gene was amplified from cDNA using the reverse transcription system: 95°C for 1 minute followed by 35 cycles of 95°C for 15 seconds, 62°C for 15 seconds, and 72°C for 15 seconds. The final extension was at 72°C for 3 minutes. Reverse transcriptase-polymerase chain reaction (RT-PCR) was carried out with a StepOne-Plus real-time PCR system with TaqMan probes (Applied Biosystems, Foster City, CA, USA) in a 20-μL reaction volume containing 10 μL of Applied Biosystems TaqMan Universal PCR Master Mix I (Cat. no. 4427788), 2 μL of cDNA, and 6 μL of RNase-free water. The specific primers are listed in Table 1, and all were purchased from Integrated DNA Technology (Coralville, IA, USA). The amplified RT-PCR products

were purified and separated using 2% agarose gel electrophoresis. The assays were repeated three times per sample.

3. Statistical analysis

Statistical analyses were performed using IBM SPSS ver. 25.0 (IBM Corp., Armonk, NY, USA). The Fisher exact test was used to compare the rates among the groups. Numerical data were compared using the Kruskal-Wallis test. If the value was significant, the Mann-Whitney *U*-test with the Bonferroni correction was used for further analysis. A *p*-value less than 0.05 was considered to indicate statistical significance.

Results

The overall outcomes of *in vitro* growth of preantral follicles and the percentage of MII oocytes are presented in Table 2. Among the three VD₃-supplemented groups (0, 25, and 50 pg/mL), the survival

Table 2. Outcomes of *in vitro* growth of mice preantral follicle under vitamin D supplementation

Variable	Vitamin D supplementation		
	0 pg/mL	25 pg/mL	50 pg/mL
No. of preantral follicles	126	126	126
No. of follicles survived at day 10 (% per initiated follicle)	124 (98.4)	125 (99.2)	126 (100)
No. of follicles with antrum formation (% per initiated follicle)	113 (89.7)	113 (89.7)	106 (84.1)
No. of follicles with spontaneous rupture (% per initiated follicle)	104 (82.5)	102 (81.0)	99 (78.6)
No. of total oocytes (% per initiated follicle)	101 (80.2)	102 (81.0)	96 (76.2)
No. of degenerated oocytes	2	1	1
No. of GV oocytes	27	29	28
No. of GVBD oocytes	43	38	39
No. of MII oocytes	31	35	29
% Per initiated follicle	24.6	27.8	23.0
% Per total oocytes	30.7	34.3	30.2

All parameters were similar among the three groups. GV, germinal vesicle; GVBD, germinal vesicle breakdown; MII, metaphase II.

Table 1. Gene primer sequences and their conditions for RT-PCR

Gene	Primer sequence	Product size (bp)	Accession number	Annealing temperature (°C)	Cycle
<i>CYP2R1</i>	F: 5'-TAGATGAGATGGATCAAGGTCAAA-3'	226	NM_177382.4	62	35
	R: 5'-CATTTGTATCCCAAGAAGGTCTC-3'				
<i>CYP27B1</i>	F: 5'-CTCTCCTGGACACTCTATGAGCTT-3'	265	NM_010009.2	62	35
	R: 5'-TGCCATAGTGACATAGGGAGACTA-3'				
<i>VDR</i>	F: 5'-AACCAGTCTTTTACCTTGGATGAC-3'	273	NM_009504.4	62	35
	R: 5'-GTAGGCTGTCAGTGTGTTGGATAG-3'				

RT-PCR, reverse transcriptase-polymerase chain reaction; F, forward; R, reverse.

of preantral follicles and the rates of antrum formation or ruptured follicles (per initiated follicle) were all comparable. The number of total oocytes per initiated follicle (80.2%, 81.0%, and 76.2%) and mature oocytes per initiated follicle (24.6%, 27.8%, and 23.0%) were also similar among the three VD₃-supplemented groups. Both *CYP2R1* and *CYP27B1* were expressed in antral and ruptured follicles, but not in preantral follicles (Figure 1). *VDR* was expressed in all three follicular stages.

Discussion

In the present work, the expression of mRNA for 25-hydroxylase (*CYP2R1*) and 1-alpha-hydroxylase (*CYP27B1*) was observed both in antral follicles and ruptured follicles, but not in preantral follicles. However, mRNA for *VDR* was expressed in preantral follicles as well as antral and ruptured follicles. It is known that *VDR* is expressed in mouse ovarian follicles [14]. In that study, however, the follicular stage-specific expression of *VDR* was not assessed. We obtained preantral follicles as well as antral and ruptured follicles separately, through mouse preantral follicle culture, and confirmed that *VDR* was expressed in all three stages. Our research is significant because we observed the follicular stage-specific expression of *VDR*.




Figure 1. Expression of mRNA for 25-hydroxylase (*CYP2R1*), 1-alpha-hydroxylase (*CYP27B1*), and vitamin D receptor (*VDR*) in the three stages of mouse ovarian follicles.

Bieche et al. [15] observed that most of the *CYP2* family, including *CYP2R1* (except *CYP2F1*), were expressed at variable levels in the human ovary. In that study, however, follicular stage-specific expression of the *CYP2* family was not assessed. In the macaque, *VDR*, *CYP2R1*, and *CYP27B1* were expressed in preantral and small antral follicles [12]. In contrast, we did not observe the expression of *CYP2R1* and *CYP27B1* mRNA in mouse preantral follicles. The reason for this difference is largely unknown. However, the absence of the two enzymes in mouse preantral follicles does not mean that VD3 has no effect on the growth of mouse preantral follicles. Based on our observations, since *VDR* is expressed in mouse preantral follicles, we can assume that VD3 can act on preantral follicles in mice. Overall, *VDR* is expressed in preantral follicles, and *CYP2R1* and *CYP27B1* are expressed in antral follicles in mice; therefore, the intrinsic VD regulating system is present in the antral follicles.

Nonetheless, VD3 supplementation *in vitro* (25 or 50 pg/mL) did not enhance the full development of mouse preantral follicles (just up to the ruptured follicle stage) or oocyte acquisition in our study. In a macaque experiment, Xu et al. [11] observed that 25 pg/mL VD3 supplementation *in vitro* improved preantral follicle survival at week 2, but 100 pg/mL supplementation *in vitro* did not. Instead, 100 pg/mL VD3 supplementation *in vitro* led to a larger diameter of antral follicles at week 5. Thus, they argued that VD locally acts on primate follicular development, in a dose- and stage-dependent manner.

The optimal supplemental concentration of VD3 for preantral follicle culture in animals is unknown. Usually, in humans, a serum level of 25OHD (major circulating VD) higher than 30 ng/mL is regarded as replete, and serum level of 25OHD less than 20 ng/mL is regarded as deficient [16]. In the study by Potashnik et al. [17], the average level of 25OHD was 9.1 ± 1.8 ng/mL in human FF and 16.9 ± 1.9 ng/mL in human serum; in contrast, the average level of active VD3 was 22.3 ± 3.4 pg/mL in human FF and 48.5 ± 8.7 pg/mL in human serum at the time of oocyte pickup. Although there have been no reports regarding the appropriate level of active VD3 in mouse FF, we assumed that the 2 VD3 concentrations in our experiment (25 or 50 pg/mL) were sufficient.

In humans, three meta-analyses have reported that women undergoing IVF who have deficient or insufficient 25OHD levels have a lower live birth rate than women who have sufficient 25OHD levels [18-20]. However, the results from individual studies are inconsistent. For example, in a review by Pacis et al. [21], one study demonstrated a negative relationship between VD status and assisted reproductive technology (ART) outcomes, while two studies showed no association; the remaining five studies concluded that ART outcomes improved after VD supplementation. Furthermore, no association of serum 25OHD levels with IVF outcomes, in terms of the clinical pregnancy rate and live birth rate, has yet been reported [22,23]. More-

over, intake of calcitriol (an active form of VD) did not enhance the clinical pregnancy rate of IVF in women with 25OHD deficiency [24]. Therefore, there is no consensus on whether serum 25OHD levels are related to the IVF pregnancy rate, or whether VD supplementation could improve the IVF pregnancy rate in women with 25OHD deficiency.

Measurement of various steroid hormone levels or genes related to the VD3 metabolic pathway after VD3 supplementation would help to elucidate the role of VD3 in folliculogenesis. In a recent study, Makieva et al. [25] found that oral VD supplementation altered the hormonal milieu of FF and the transcriptomic profile of luteinized granulosa cells in women with 25OHD deficiency. They found upregulation of *VDR*, glutathione-S-transferase A3 (*GSTA3*), and the interleukin-21 receptor, and downregulation of prostaglandin-endoperoxide synthase 2 (*PTGS2*), Kruppel-like factor 4 (*KLF4*), transient receptor potential cation channel subfamily C member (*TRPC4*), vascular endothelial growth factor, retinoid X receptor beta, and advanced glycation end-product specific receptor by oral VD supplementation. The mechanistic pathway of folliculogenesis after VD3 supplementation *in vitro* should be further investigated in animal models.

In conclusion, in the current study, we found follicular stage-specific expression of *VDR*, *CYP2R1*, and *CYP27B1* in mice. Unfortunately, VD3 supplementation *in vitro* (25 or 50 pg/mL) was not helpful for the full development of preantral follicles and the resultant oocyte acquisition. Further studies are needed to verify whether VD3 supplementation *in vitro* is effective for the stage-specific development of mouse preantral follicles.

Conflict of interest

Byung Chul Jee is the editor-in-chief of the journal, but he was not involved in the peer reviewer selection, evaluation, or decision process of this article. No other potential conflicts of interest relevant to this article are reported.

ORCID

Yoo Jin Shim	https://orcid.org/0000-0002-6895-3321
Yeon Hee Hong	https://orcid.org/0000-0002-9709-4175
Jaewang Lee	https://orcid.org/0000-0001-6801-7149
Byung Chul Lee	https://orcid.org/0000-0003-2289-6090

Author contributions

Conceptualization: YJS, YHH, BCJ. Data curation: YJS, YHH. Formal analysis: YJS, YHH, BCJ. Methodology: YHH, JL, BCJ. Project adminis-

tration: all authors. Writing-original draft: YJS, YHH, BCJ. Writing-review & editing: YJS, YHH, BCJ.

References

- Bouillon R, Carmeliet G, Daci E, Segaeert S, Verstuyf A. Vitamin D metabolism and action. *Osteoporos Int* 1998;8 Suppl 2:S13–9.
- Wagner CL, Taylor SN, Dawodu A, Johnson DD, Hollis BW. Vitamin D and its role during pregnancy in attaining optimal health of mother and fetus. *Nutrients* 2012;4:208–30.
- Anagnostis P, Karras S, Goulis DG. Vitamin D in human reproduction: a narrative review. *Int J Clin Pract* 2013;67:225–35.
- Bikle DD. Vitamin D metabolism, mechanism of action, and clinical applications. *Chem Biol* 2014;21:319–29.
- Merhi Z, Doswell A, Krebs K, Cipolla M. Vitamin D alters genes involved in follicular development and steroidogenesis in human cumulus granulosa cells. *J Clin Endocrinol Metab* 2014;99:E1137–45.
- Irani M, Merhi Z. Role of vitamin D in ovarian physiology and its implication in reproduction: a systematic review. *Fertil Steril* 2014;102:460–8.
- Fang F, Ni K, Cai Y, Shang J, Zhang X, Xiong C. Effect of vitamin D supplementation on polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. *Complement Ther Clin Pract* 2017;26:53–60.
- Anifandis GM, Dafopoulos K, Messini CI, Chalvatzas N, Liakos N, Pournaras S, et al. Prognostic value of follicular fluid 25-OH vitamin D and glucose levels in the IVF outcome. *Reprod Biol Endocrinol* 2010;8:91.
- Ciepiela P, Duleba AJ, Kowaleczko E, Chelstowski K, Kurzawa R. Vitamin D as a follicular marker of human oocyte quality and a serum marker of in vitro fertilization outcome. *J Assist Reprod Genet* 2018;35:1265–76.
- Yao X, Zhang G, Guo Y, Ei-Samahy M, Wang S, Wan Y, et al. Vitamin D receptor expression and potential role of vitamin D on cell proliferation and steroidogenesis in goat ovarian granulosa cells. *Theriogenology* 2017;102:162–73.
- Xu J, Hennebold JD, Seifer DB. Direct vitamin D₃ actions on rhesus macaque follicles in three-dimensional culture: assessment of follicle survival, growth, steroid, and antiMullerian hormone production. *Fertil Steril* 2016;106:1815–20.
- Xu J, Lawson MS, Xu F, Du Y, Tkachenko OY, Bishop CV, et al. Vitamin D₃ regulates follicular development and intrafollicular vitamin D biosynthesis and signaling in the primate ovary. *Front Physiol* 2018;9:1600.
- Hong YH, Kim SJ, Kim SK, Lee SC, Jun JH, Jee BC, et al. Impact of imatinib or dasatinib coadministration on in vitro preantral follicle development and oocyte acquisition in cyclophosphamide-treated mice. *Clin Exp Reprod Med* 2020;47:269–76.
- Shahbazi M, Jeddi-Tehrani M, Zareie M, Salek-Moghaddam A, Akhondi MM, Bahmanpoor M, et al. Expression profiling of vitamin D receptor in placenta, decidua and ovary of pregnant mice. *Placenta* 2011;32:657–64.
- Bieche I, Narjoz C, Asselah T, Vacher S, Marcellin P, Lidereau R, et al. Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. *Pharmacogenet Genomics* 2007;17:731–42.
- Firouzabadi RD, Rahmani E, Rahsepar M, Firouzabadi MM. Value of follicular fluid vitamin D in predicting the pregnancy rate in an IVF program. *Arch Gynecol Obstet* 2014;289:201–6.
- Potashnik G, Lunenfeld E, Levitas E, Itskovitz J, Albutiano S, Yankowitz N, et al. The relationship between endogenous oestradiol and vitamin D₃ metabolites in serum and follicular fluid during ovarian stimulation for in-vitro fertilization and embryo transfer. *Hum Reprod* 1992;7:1357–60.
- Lv SS, Wang JY, Wang XQ, Wang Y, Xu Y. Serum vitamin D status and in vitro fertilization outcomes: a systematic review and meta-analysis. *Arch Gynecol Obstet* 2016;293:1339–45.
- Chu J, Gallos I, Tobias A, Tan B, Eapen A, Coomarasamy A. Vitamin D and assisted reproductive treatment outcome: a systematic review and meta-analysis. *Hum Reprod* 2018;33:65–80.
- Zhao J, Huang X, Xu B, Yan Y, Zhang Q, Li Y. Whether vitamin D was associated with clinical outcome after IVF/ICSI: a systematic review and meta-analysis. *Reprod Biol Endocrinol* 2018;16:13.
- Pacis MM, Fortin CN, Zarek SM, Mumford SL, Segars JH. Vitamin D and assisted reproduction: should vitamin D be routinely screened and repleted prior to ART? A systematic review. *J Assist Reprod Genet* 2015;32:323–35.
- Franasiak JM, Molinaro TA, Dubell EK, Scott KL, Ruiz AR, Forman EJ, et al. Vitamin D levels do not affect IVF outcomes following the transfer of euploid blastocysts. *Am J Obstet Gynecol* 2015;212:315.
- Cozzolino M, Busnelli A, Pellegrini L, Riviello E, Vitagliano A. How vitamin D level influences in vitro fertilization outcomes: results of a systematic review and meta-analysis. *Fertil Steril* 2020;114:1014–25.
- Doryanizadeh L, Morshed-Behbahani B, Parsanezhad ME, Dabaghmanesh MH, Jokar A. Calcitriol effect on outcomes of in vitro fertilization in infertile women with vitamin D deficiency: a double-blind randomized clinical trial. *Z Geburtshilfe Neonatol* 2021;225:226–31.
- Makieva S, Reschini M, Ferraris S, Bonesi F, Polledri E, Fustinoni S, et al. Oral Vitamin D supplementation impacts gene expression in granulosa cells in women undergoing IVF. *Hum Reprod* 2021;36:130–44.